CVS vs Walgreens: What 8,000 Customer Reviews Reveal About the Pharmacy Wars

The American pharmacy industry is undergoing a structural transformation. Store closures, labor shortages, PBM reform debates, and the encroachment of Amazon Pharmacy and cost-plus disruptors have created an operating environment that management teams on both sides describe, with remarkable understatement, as "challenging." For equity analysts covering CVS Health (CVS) and Walgreens Boots Alliance (WBA), the fundamental question is deceptively simple: which chain is better positioned to retain customers through the transition?

Traditional data sources offer partial answers. Same-store sales comps arrive quarterly with a lag. Prescription volume data from IQVIA is useful but does not capture the front-of-store experience. Foot traffic data from geospatial providers shows who enters but not how they feel about the visit. Customer review data fills a critical gap: it captures the qualitative experience of the pharmacy visit—wait times, pharmacist interactions, store conditions, digital tool satisfaction—at the individual location level, in near real time.

ReviewSignal analyzed 8,247 customer reviews across 1,438 locations for CVS and Walgreens during the second half of 2025. What we found tells a story of two chains on divergent sentiment trajectories—and suggests that the gap may widen further before it narrows.

Our dataset comprises publicly available customer reviews posted between July 1 and December 31, 2025, sourced from major review platforms. Locations were matched to company-reported store lists using address normalization and geocoding. Reviews were processed through ReviewSignal's proprietary NLP pipeline, which extracts sentiment scores (on a continuous -1.0 to +1.0 scale), identifies topic categories (pharmacy service, wait times, store cleanliness, staff friendliness, mobile app experience, and pricing), and flags operational anomalies.

To ensure statistical robustness, we excluded locations with fewer than three reviews during the analysis period and applied inverse-propensity weighting to correct for differences in review volume across geographies. All sentiment scores reported below are weighted averages unless otherwise noted. The analysis covers 782 CVS locations and 656 Walgreens locations meeting our inclusion criteria.

The aggregate numbers tell a clear story. CVS holds a 12-point sentiment advantage over Walgreens on our normalized scale, and more importantly, the trajectories are diverging. CVS sentiment improved modestly over the six-month period (+0.04), while Walgreens deteriorated meaningfully (-0.07). The gap is widening.

But aggregate numbers obscure the operational nuances that matter for investment analysis. The category-level breakdown reveals where each chain is winning and losing the customer experience battle.

Pharmacy wait times represent the single largest sentiment gap between the two chains. Walgreens scores a deeply negative -0.31 in this category, reflecting widespread customer frustration with prescription fulfillment delays. CVS is negative too at -0.12—wait times are a pain point across the industry—but the 19-point gap suggests that Walgreens' staffing challenges and operational execution in the pharmacy are meaningfully worse. Review language frequently references "hours" rather than "minutes" when describing Walgreens waits, a qualitative signal that aligns with the quantitative scores.

Pharmacist satisfaction measures sentiment specifically directed at the pharmacist interaction, separate from wait time complaints. Both chains score positively here, but CVS's 12-point lead suggests that its pharmacists are perceived as more helpful, knowledgeable, or attentive. This may reflect CVS's investments in clinical pharmacist training programs and its broader health services strategy, which positions pharmacists as healthcare providers rather than merely prescription dispensers.

Store cleanliness has emerged as a surprisingly important differentiator. Walgreens' slightly negative score reflects a pattern of complaints about disorganized shelves, poorly lit interiors, and visible maintenance issues—signals that may indicate underinvestment in store-level capital expenditure. For investors, store condition is a leading indicator of management's commitment to the physical retail experience. When stores start looking neglected, foot traffic erosion typically follows within two to three quarters.

Mobile app experience favors CVS by 10 points. CVS's app, which integrates prescription management, MinuteClinic scheduling, ExtraCare rewards, and health data tracking, receives notably more positive reviews than the Walgreens equivalent. In an era where pharmacy loyalty is increasingly mediated through digital interfaces, this advantage compounds over time.

Walgreens holds narrow leads in front-of-store staff friendliness and pricing perception. The pricing advantage likely reflects Walgreens' more aggressive promotional cadence and its partnership with retail media networks to deliver targeted discounts. However, these two categories have weaker correlations with repeat visit intent than pharmacy-specific factors, limiting their strategic significance.

The national averages mask significant geographic variation. Our location-level analysis reveals sentiment hotspots and cold spots that align with known operational and competitive dynamics.

CVS performs strongest in the Northeast and Mid-Atlantic, its historic base, where store density is highest and brand loyalty is most entrenched. Boston, Philadelphia, and the greater New York metro area all show CVS sentiment scores 15 to 25 points above the national average. This is unsurprising given CVS's heritage as a New England company, but it underscores the importance of geographic concentration in pharmacy retail.

Walgreens shows relative strength in the Midwest, particularly in Chicago (its headquarters market) and across Illinois, Wisconsin, and Michigan. However, even in these favorable geographies, Walgreens' absolute sentiment scores are lower than CVS's scores in CVS-favorable markets. The Midwest advantage is relative, not absolute.

The most concerning geography for Walgreens is the Sun Belt. Across Texas, Florida, Arizona, and Georgia—the fastest-growing pharmacy markets in the country—Walgreens sentiment scores are deteriorating at roughly twice the national rate. New residents in these markets have no legacy brand attachment; they choose pharmacies based on experience, convenience, and digital tools. Walgreens is losing this competition at the location level.

The ultimate test of any alternative data signal is whether it predicts economically meaningful outcomes. We examined the relationship between ReviewSignal's sentiment scores and publicly reported comparable-store sales growth for both chains over the trailing eight quarters.

The correlation is strong and statistically significant. Our composite pharmacy sentiment score explains approximately 34% of the variance in same-store prescription volume growth (R-squared = 0.34, p < 0.01) with a lead time of approximately one quarter. This means that sentiment shifts observable in review data during Q3 are predictive of prescription volume trends reported in Q4 earnings.

For front-of-store sales, the relationship is weaker but still meaningful (R-squared = 0.19), consistent with the intuition that discretionary front-store purchases are influenced by the overall store experience but also by promotional activity and seasonal factors that review data captures less directly.

The sentiment data supports a directional view that CVS is better positioned operationally than Walgreens in the current environment. Several factors reinforce this interpretation:

Walgreens' sentiment deterioration is accelerating, not stabilizing. The month-over-month trajectory within our six-month window shows no evidence of a bottoming pattern. If anything, the rate of decline increased in Q4 2025, coinciding with reports of further pharmacist staffing cuts and store closure announcements. For investors looking for a catalyst to close short positions or initiate long positions in WBA, the review data does not yet provide that signal.

CVS's digital advantage is compounding. The mobile app experience gap, while modest in absolute terms, has implications that extend beyond app store ratings. A superior digital interface drives higher refill adherence rates, which drives higher prescription revenue per customer, which drives higher lifetime value. CVS is building a flywheel that Walgreens has not yet matched.

Geographic exposure matters. Walgreens' relative weakness in Sun Belt markets puts it on the wrong side of the demographic migration trend. Population growth is concentrated in precisely the markets where Walgreens is losing the customer experience competition. This structural headwind will not reverse quickly.

CVS and Walgreens are part of ReviewSignal's expanding retail coverage universe. While our core coverage has historically centered on the restaurant industry—where we track 101 chains across 44,500+ locations—the same NLP infrastructure and propagation models that power our restaurant analytics apply directly to pharmacy retail, grocery, and other consumer-facing sectors.

Drugstore chains share key analytical properties with restaurants: high location counts, frequent customer interactions generating steady review flow, strong brand-level identities that enable cross-location sentiment propagation modeling, and direct ties to publicly traded equities. Our Echo Engine, originally calibrated for restaurant chains, has been extended to model sentiment contagion within CVS and Walgreens networks, producing propagation forecasts that institutional clients can incorporate into their WBA/CVS pair trades and sector allocation models.

The pharmacy wars are far from over. Regulatory changes to PBM structures, the continued expansion of Amazon Pharmacy, and the uncertain trajectory of healthcare utilization post-pandemic will all shape the competitive landscape in ways that no single data source can fully predict. But for investors seeking a granular, location-level, real-time view of which chain is winning the customer experience battle block by block and city by city, 8,000 customer reviews tell a story that quarterly earnings calls cannot. And right now, that story favors CVS.